Adflu 50mg Injection

Treatment of B-Cell chronic lymphocytic leukemia (blood cancer)

Treatment of B-Cell chronic lymphocytic leukemia (blood cancer)

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Admatrone 250mg Tablet, but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Admatrone 250mg Tablet are:
Fatigue
Headache, Fever High blood pressure
Rash
Indigestion
Nausea
diarrhea, or constipation Loss of appetite Low blood count,
Hair loss,

If a person has a history of renal, liver, cardiovascular illness, hypoglycemia, or fluid retention, they should avoid taking Admatrone 250mg Tablet. It should be taken two hours before or after meals on an empty stomach. It is not advised for women or children to use Admatrone. Admatrone 250mg Tablet can interact with other medications; therefore, it's best to let your doctor know before taking any other medications. When treating prostate cancer, this medication is frequently used with prednisolone. The medication should not be broken, crushed, or chewed.

Adflu 50mg Injection is given slowly in the veins; it is generally advised to receive lots of water before and after the injection to protect the kidneys. Do not use the same injection or syringe for another injection, as there is a chance of interaction. Always check the vial of injection before using it for discoloration or any kind of particulate matter, and shake well for uniform mixing of the product. Adflu 50mg Injection is administered once every 3-4 weeks or for 5 consecutive days. Always consult your doctor before taking the vaccine, especially if you have a family history of blood disorders, heart problems, lung problems, pain in the limbs, or kidney problems.

Alas, S., Emmanouilides, C., & Bonavida, B. (2023). Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clinical cancer research, 7(3), 709-723.
Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007 Jul 21;370(9583):230-239.
Keating, M. J. (2020). Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. In Seminars in Oncology (Vol. 17, No. 5 Suppl 8, pp. 49-62).
Puccio, C. A., Mittelman, A., Lichtman, S. M., Silver, R. T., Budman, D. R., Ahmed, T., & Arlin, Z. A. (2024). A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. Journal of Clinical Oncology, 9(9), 1562-1569.
Tam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K. A., & Keating, M. J. (2025). Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 112(4), 975-980.